In conclusion, our data demonstrated that SGLT2 inhibition with empagliflozin ameliorated myocardial fibrosis, enhanced left ventricular function, and increased survival time in a non-diabetic rat model ventricular fibrillation CA and CPR. The gene discussed is SLC5A2; the disease is Myocardial fibrosis.